Abstract
Background: Lactucine is related to the sesquiterpene lactone group of naturally occurring compounds and has a variety of pharmacological effects including anticancer properties found in Chicory, Wormwood, Laurus nobilis, Pyrethrum, Chamomile, etc. Lactucine has an anticancer effect which may induce apoptosis in cancerous cells and protect other cells from getting infected.
Objective: In this study, Lactucine and its derivatives were screened, and performed their in silico docking study with the proteins involved in the apoptosis-inducing effect in human leukemia cancer.
Methods: The three-dimensional structure of lactucine and its derivatives were retrieved in the SDF format. Active sites of protein structures were determined by Sitemap. LigPrep module was used for geometrical refining of chemical structures of lactucine and its derivatives. The protein preparation wizard of Maestro (Schrodinger) was used for protein preparation. From the receptor-complex structure, the cocrystallized ligands were removed from the active site position of the receptor chain. All ligands were docked using default Glide settings for a grid centered on the ligand and structure. Flexible docking was performed using the extra precision (XP) feature of Glide module. The best docking poses for the lactucine and their derivatives were selected based on their docking score. The ADMET properties of lactucine 15- oxalate have been predicted by admetSAR software.
Results: Proteins and ligands three-dimensional structures were retrieved from PDB and Pubchem databases, respectively. All lactucine derivatives suitably docked on the apoptosis-inducing proteins with ample Glide scores Lactucin 15-oxalate interacts with proteins which are responsible for apoptosis with a maximum of six H-bonds. Other types of interactions are also involved, like Pi-cation, Pi-Pi stacking, salt bridges, and halogen bonds. Protein CDK-4 has shown the highest number of H-bond (LYS142 salt bridges), ALA16, VAL14, ASP99, LYS35, TYR17, and ASN145) with the Lactucin 15-oxalate. ADMET properties of lactucin 15-oxalate met with the criteria of being eligible to be a novel drug for the treatment of human leukemia cancer. The Dock score of both the Dasatinib drug and the lactucine-15-oxalate with the apoptosis-inducing protein stipulates that the selected ligand has equitable interaction with the target proteins.
Conclusion: In this study, lactucine derivatives were docked with apoptosis-inducing proteins for the prediction of its anticancer effect. Lactucin15-oxalate has shown the highest binding affinity for the CDK-4 target and can be used as a lead compound for cancer treatment. Glide and Dock score for docking of lactucin 15-oxalate with CDK-4, well as the number of hydrogen bonding, is in agreement to use this ligand for study. These in silico results are valuable to proceed with the in vitro and in vivo studies related to the anti-cancer role of lactucin 15-oxalate.
Graphical Abstract
[http://dx.doi.org/10.1016/j.jep.2004.06.031] [PMID: 15507374]
[http://dx.doi.org/10.1038/bjc.1972.33] [PMID: 4561027]
[http://dx.doi.org/10.1007/s13277-016-5035-9] [PMID: 27059734]
[http://dx.doi.org/10.1016/0092-8674(86)90004-8] [PMID: 3955651]
[http://dx.doi.org/10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7] [PMID: 10567915]
[http://dx.doi.org/10.1073/pnas.97.26.14376] [PMID: 11121041]
[http://dx.doi.org/10.1038/nrc1695] [PMID: 16148884]
[http://dx.doi.org/10.1038/35037722] [PMID: 11048729]
[http://dx.doi.org/10.1038/35037710] [PMID: 11048727]
[http://dx.doi.org/10.1002/cbin.11137] [PMID: 30958602]
[http://dx.doi.org/10.1038/nrm2312] [PMID: 18073771]
[http://dx.doi.org/10.1146/annurev.cellbio.15.1.269] [PMID: 10611963]
[http://dx.doi.org/10.1038/sj.onc.1206044] [PMID: 12483536]
[http://dx.doi.org/10.1021/ja00172a038]
[http://dx.doi.org/10.1007/s00044-011-9910-z]
[http://dx.doi.org/10.1039/C8MD00472B] [PMID: 30774861]
[http://dx.doi.org/10.1093/nar/gkv1192] [PMID: 26553801]
[http://dx.doi.org/10.1016/j.ejmech.2013.12.046] [PMID: 24508781]
[http://dx.doi.org/10.1186/1742-4682-10-1] [PMID: 23276293]
[http://dx.doi.org/10.3329/bjp.v11i2.26729]
[http://dx.doi.org/10.1126/science.271.5246.163] [PMID: 8539615]
[http://dx.doi.org/10.1021/jm100112j] [PMID: 20345171]
[http://dx.doi.org/10.1016/S1074-5521(02)00245-4] [PMID: 12445771]
[http://dx.doi.org/10.1006/jmbi.2000.4040] [PMID: 10970741]
[http://dx.doi.org/10.1073/pnas.96.17.9459] [PMID: 10449714]
[http://dx.doi.org/10.1016/S0165-6147(02)02027-8] [PMID: 12084634]
[http://dx.doi.org/10.1186/1471-2105-10-S15-S10]
[http://dx.doi.org/10.1371/journal.pone.0078085] [PMID: 24205103]
[http://dx.doi.org/10.1093/protein/4.2.155] [PMID: 2075190]